Hospital Mater Dei S.A. Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Hospital Mater Dei S.A. (BVMF:MATD3) just released its latest third-quarter results and things are looking bullish. It was overall a positive result, with revenues beating expectations by 2.9% to hit R$660m. Hospital Mater Dei reported statutory earnings per share (EPS) R$0.16, which was a notable 11% above what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

After the latest results, the nine analysts covering Hospital Mater Dei are now predicting revenues of R$2.68b in 2027. If met, this would reflect a decent 11% improvement in revenue compared to the last 12 months. Yet prior to the latest earnings, the analysts had been anticipated revenues of R$2.69b and earnings per share (EPS) of R$0.73 in 2027. So we can see that while the consensus made no real change to its revenue estimates, it also no longer provides an earnings per share estimate. This suggests that revenues are what the market is focusing on after the latest results.

View our latest analysis for Hospital Mater Dei

There's been no real change to the consensus price target of R$7.32, with Hospital Mater Dei seemingly executing in line with expectations. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Hospital Mater Dei analyst has a price target of R$9.00 per share, while the most pessimistic values it at R$6.30. There are definitely some different views on the stock, but the range of estimates is not wide enough as to imply that the situation is unforecastable, in our view.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Hospital Mater Dei's revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 8.9% growth on an annualised basis. This is compared to a historical growth rate of 11% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 12% annually. Factoring in the forecast slowdown in growth, it seems obvious that Hospital Mater Dei is also expected to grow slower than other industry participants.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Hospital Mater Dei's revenue is expected to perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

At least one of Hospital Mater Dei's nine analysts has provided estimates out to 2028, which can be seen for free on our platform here.

It is also worth noting that we have found 1 warning sign for Hospital Mater Dei that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.